Jointing/Cutting Sample Clauses

Jointing/Cutting. The minimum overlap shall be 500 mm. In applications where the geotextile is subject to tensile stress, the overlap shall be increased by 100 mm. Overlaps shall be sown or stapled as per the manufacturer’s recommendations. Stitching should be at least 50 mm back from the free edges of the fabric.
AutoNDA by SimpleDocs

Related to Jointing/Cutting

  • Road Surfaces (1) Grade, shape, crown, and/or outslope surface and shoulders.

  • Screening 3.13.1 Refuse containers located outside the building shall be fully screened from adjacent properties and from streets by means of opaque fencing or masonry walls with suitable landscaping.

  • Infrastructure Improvements The design, redevelopment and construction and completion of certain infrastructure improvements, including sewer, stormwater, electrical and water main improvements, along with other similar improvements.

  • Debriefing If a post-award debriefing is given to requesting offerors, the Government shall disclose the following information, if applicable:

  • Credit for Project Work In order to compensate PURCHASER for project work that PURCHASER agrees to complete under the section titled, “Project Work,” of this contract, STATE agrees to credit PURCHASER’s timber account in the sum of $46,657 upon completion of and STATE’s acceptance of all work, unless otherwise approved in writing by STATE. PURCHASER may request partial credit for project work when PURCHASER has completed and STATE has accepted project work, in accordance with the following credit schedule: Partial credit amount of $24,999 (Project No. 1 completion) Partial credit amount of $ 545 (Project No. 2 completion) Partial credit amount of $ 2,721 (Project No. 3 completion) Partial credit amount of $ 1,753 (Project No. 4 completion) Partial credit amount of $16,639 (Project No. 5 completion)

  • Disturbance Analysis Data Exchange The Parties will cooperate with one another and the NYISO in the analysis of disturbances to either the Large Generating Facility or the New York State Transmission System by gathering and providing access to any information relating to any disturbance, including information from disturbance recording equipment, protective relay targets, breaker operations and sequence of events records, and any disturbance information required by Good Utility Practice.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Sub-projects 1. The Participating Bank shall make Sub-loans to Beneficiaries and appraise, review, approve, and supervise Sub-projects in accordance with the criteria, conditions and procedures set forth in the Operations Manual, including, inter alia, the following eligibility criteria:

  • Projects The Annexes attached hereto describe the specific projects and the policy reforms and other activities related thereto (each, a “Project”) that the Government will carry out, or cause to be carried out, in furtherance of this Compact to achieve the Objectives and the Compact Goal.

  • Partnership Working 7.1 Partnerships will be supported by local authorities on four levels between:

Time is Money Join Law Insider Premium to draft better contracts faster.